Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Altered blood flow leads to falls in elderly people: Research

A new study shows that altered blood flow in the brain due to high blood pressure and other conditions may lead to falls in elderly people. The research will be published in the May 18, 2010, issue of Neurology, the medical journal of the American Academy of Neurology. Each year, unintentional falls in the United States account for more than 16,000 deaths and 1.8 million emergency room visits.

18 May 2010

BaroFold licenses PreEMT Technology to Nuron Biotech for development of BaroFeron

BaroFold, Inc. today announced that it has entered into an agreement to exclusively license its PreEMT™ Technology to Nuron Biotech for the development of BaroFeron™ and follow-on interferon beta products. BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis. Specific terms of the agreement are not disclosed.

17 May 2010

United Spinal Association and ICS co-sponsor first annual conference to empower women with disabilities

United Spinal Association and Independence Care System (ICS), are co-sponsoring the first annual conference to improve the lives, health, and well-being of women with disabilities.

15 May 2010

BioMS reports consolidated net income of $6.5M for first-quarter 2010 compared to net loss of $3.8M in 2009

BioMS Medical Corp., today announced financial and operational results for the three months ended March 31, 2010.

15 May 2010

Data from RGN-259 study published in Archives of Ophthalmology

RegeneRx Biopharmaceuticals, Inc. announced today the publication of the first human data from a case study of patients evaluated with its ophthalmic product candidate RGN-259. The data have been published in the May 2010 issue of Archives of Ophthalmology, an American Medical Association peer-reviewed journal.

14 May 2010

Children with epilepsy say their quality of life is comparable to that of healthy siblings

Children with epilepsy often face multiple challenges - not only seizures but learning, cognitive and school difficulties, side effects from medication, and, not surprisingly, social stigma from their peers.

14 May 2010

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended March 31, 2010 and provided an update on its corporate developments.

14 May 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.

14 May 2010

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

GTC Biotherapeutics, Inc. today reported its financial results for the first fiscal quarter ended April 4, 2010. The total net loss for the first quarter was $7.7 million, or $0.26 per share, compared to $10.4 million, or $0.99 per share, for the first quarter of 2009.

12 May 2010

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Evotec AG today reported financial results and corporate updates for the first quarter of 2010.

12 May 2010

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Critical Outcome Technologies Inc. announced today that it received a favourable Pre-Investigational New Drug (pre-IND) gap analysis report from an independent team that reviewed its novel oncology drug candidate COTI-2. This represents an important milestone as the Company draws closer to a Phase 1 clinical trial.

12 May 2010

MediciNova announces $15 million senior secured term loan with Oxford Finance

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today announced that it has entered into a $15 million senior secured term loan with Oxford Finance Corporation.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.

11 May 2010

UCF receives $1.9M NIH grant for exploring new ways of reversing damage caused by MS

A National Institutes of Health grant will help University of Central Florida researchers explore new ways to potentially reverse the damage caused by multiple sclerosis and other neurological disorders.

11 May 2010

Imperial College London and McGill University expand scientific collaboration

Neurological research and clinical care received a significant boost today as Imperial College London and McGill University of Montreal entered an agreement enabling them to work more closely together in this field.

11 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

Bone marrow stem cells show promise in multiple sclerosis

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Altered blood flow leads to falls in elderly people: Research

BaroFold licenses PreEMT Technology to Nuron Biotech for development of BaroFeron

United Spinal Association and ICS co-sponsor first annual conference to empower women with disabilities

BioMS reports consolidated net income of $6.5M for first-quarter 2010 compared to net loss of $3.8M in 2009

Data from RGN-259 study published in Archives of Ophthalmology

Children with epilepsy say their quality of life is comparable to that of healthy siblings

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

Evotec first-quarter operating loss decreases 93% to € 1.5 m

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

MediciNova announces $15 million senior secured term loan with Oxford Finance

Transition Therapeutics reports increased revenue in third-quarter 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

UCF receives $1.9M NIH grant for exploring new ways of reversing damage caused by MS

Imperial College London and McGill University expand scientific collaboration

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Genzyme to initiate $2 billion stock buyback

RayBiotech announces biomarker grant winners

Bone marrow stem cells show promise in multiple sclerosis

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in